Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1937321 | 0.98 | GRIN1 (0.44) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL2530809 | 0.98 | GRIN1 (0.44) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL29775660 | 0.98 | GRIN1 (0.44) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL1919376 | 0.98 | GRIN1 (0.44) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| SCHEMBL29857697 | 0.91 | GRIN1 (0.47) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| SCHEMBL1515504 | 0.91 | GRIN1 (0.47) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| SCHEMBL31116789 | 0.91 | GRIN1 (0.51) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL1515631 | 0.90 | GRIN1 (0.46) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 | |
| SCHEMBL27481787 | 0.90 | GRIN1 (0.54) | GRIN1GRIN2AGRIN2BHSD11B1 | |
| Hydrochloric Acid SCHEMBL18742775 | 0.90 | GRIN1 (0.46) | GRIN1GRIN2AGRIN2BOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3981395-A1 | LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS | Oryzon Genomics, S.A. (ES) | 2022-04-13 | — | — | EP | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | claimed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | claimed |
| EP-2750671-A2 | LYSINE DEMETHYLASE INHIBITORS FOR THROMBOSIS AND CARDIOVASCULAR DISEASES | Oryzon Genomics, S.A. (ES) | 2014-07-09 | — | — | EP | claimed |
| WO-2012156537-A2 | LYSINE DEMETHYLASE INHIBITORS FOR THROMBOSIS AND CARDIOVASCULAR DISEASES | ORYZON GENOMICS, S.A. (ES) | 2012-11-22 | — | — | WO | claimed |
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025093590-A1 | HETEROARYL ESTER DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| EP-3956033-B1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | GRIN1 452/4885GRIN2A 1629/4885GRIN2B 1228/4885 |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | GRIN1 1494/4885GRIN2A 1611/4885GRIN2B 1555/4885 |
| US-12103902-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | GRIN1 2993/4885GRIN2A 3296/4885GRIN2B 3797/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | GRIN1 932/4885GRIN2A 1233/4885GRIN2B 1603/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | GRIN1 433/4885GRIN2A 740/4885GRIN2B 691/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | GRIN1 424/4885GRIN2A 387/4885GRIN2B 372/4885 |
| US-12338262-B2 | Modulators of TNF-alpha activity | TNF, TNFRSF1A, NFKBIA | GRIN1 1692/4885GRIN2A 2219/4885GRIN2B 3033/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | GRIN1 433/4885GRIN2A 740/4885GRIN2B 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.